Published in J Exp Med on August 04, 1997
Viral and host factors in human respiratory syncytial virus pathogenesis. J Virol (2007) 3.19
Lack of antibody affinity maturation due to poor Toll-like receptor stimulation leads to enhanced respiratory syncytial virus disease. Nat Med (2008) 3.17
CD4 T cell cytokine differentiation: the B cell activation molecule, OX40 ligand, instructs CD4 T cells to express interleukin 4 and upregulates expression of the chemokine receptor, Blr-1. J Exp Med (1998) 2.45
A role for immune complexes in enhanced respiratory syncytial virus disease. J Exp Med (2002) 2.34
Viral induction of a chronic asthma phenotype and genetic segregation from the acute response. J Clin Invest (2002) 2.06
Biological challenges and technological opportunities for respiratory syncytial virus vaccine development. Immunol Rev (2011) 2.04
Respiratory syncytial virus infection: immune response, immunopathogenesis, and treatment. Clin Microbiol Rev (1999) 1.83
Respiratory syncytial virus G and/or SH protein alters Th1 cytokines, natural killer cells, and neutrophils responding to pulmonary infection in BALB/c mice. J Virol (1999) 1.71
Differential pathogenesis of respiratory syncytial virus clinical isolates in BALB/c mice. J Virol (2011) 1.61
Influenza virus lung infection protects from respiratory syncytial virus-induced immunopathology. J Exp Med (2000) 1.57
NK T cells contribute to expansion of CD8(+) T cells and amplification of antiviral immune responses to respiratory syncytial virus. J Virol (2002) 1.55
Regulatory T cells promote early influx of CD8+ T cells in the lungs of respiratory syncytial virus-infected mice and diminish immunodominance disparities. J Virol (2009) 1.51
Eliminating a region of respiratory syncytial virus attachment protein allows induction of protective immunity without vaccine-enhanced lung eosinophilia. J Exp Med (1998) 1.48
Atypical pulmonary eosinophilia is mediated by a specific amino acid sequence of the attachment (G) protein of respiratory syncytial virus. J Exp Med (1998) 1.43
Secreted respiratory syncytial virus G glycoprotein induces interleukin-5 (IL-5), IL-13, and eosinophilia by an IL-4-independent mechanism. J Virol (1999) 1.42
Respiratory syncytial virus G and/or SH glycoproteins modify CC and CXC chemokine mRNA expression in the BALB/c mouse. J Virol (2000) 1.39
Respiratory syncytial virus interferon antagonist NS1 protein suppresses and skews the human T lymphocyte response. PLoS Pathog (2011) 1.28
Induction of Th-1 and Th-2 responses by respiratory syncytial virus attachment glycoprotein is epitope and major histocompatibility complex independent. J Virol (1999) 1.25
Pulmonary immunity and immunopathology: lessons from respiratory syncytial virus. Expert Rev Vaccines (2008) 1.23
Respiratory syncytial virus (RSV) G glycoprotein is not necessary for vaccine-enhanced disease induced by immunization with formalin-inactivated RSV. J Virol (2004) 1.21
Respiratory syncytial virus fusion protein mediates inhibition of mitogen-induced T-cell proliferation by contact. J Virol (2002) 1.19
Respiratory syncytial virus vaccine development. Expert Rev Vaccines (2011) 1.18
The number of respiratory syncytial virus (RSV)-specific memory CD8 T cells in the lung is critical for their ability to inhibit RSV vaccine-enhanced pulmonary eosinophilia. J Immunol (2008) 1.15
Vbeta14(+) T cells mediate the vaccine-enhanced disease induced by immunization with respiratory syncytial virus (RSV) G glycoprotein but not with formalin-inactivated RSV. J Virol (2004) 1.15
The host response and molecular pathogenesis associated with respiratory syncytial virus infection. Future Microbiol (2009) 1.15
Respiratory syncytial virus infection and G and/or SH protein expression contribute to substance P, which mediates inflammation and enhanced pulmonary disease in BALB/c mice. J Virol (2000) 1.12
Regulation of cytokine production by virus-specific CD8 T cells in the lungs. J Virol (2008) 1.11
Protective and dysregulated T cell immunity in RSV infection. Curr Opin Virol (2013) 1.08
Single intranasal immunization with recombinant adenovirus-based vaccine induces protective immunity against respiratory syncytial virus infection. J Virol (2007) 1.08
Dual role of respiratory syncytial virus glycoprotein fragment as a mucosal immunogen and chemotactic adjuvant. PLoS One (2012) 1.05
A highly attenuated recombinant human respiratory syncytial virus lacking the G protein induces long-lasting protection in cotton rats. Virol J (2010) 1.02
Overcoming T cell-mediated immunopathology to achieve safe RSV vaccination. Future Virol (2008) 1.01
Proliferative expansion and acquisition of effector activity by memory CD4+ T cells in the lungs following pulmonary virus infection. J Immunol (2008) 0.99
Type 2 cytokines predominate in the human CD4(+) T-lymphocyte response to Epstein-Barr virus nuclear antigen 1. J Virol (2000) 0.98
HLA class I-restricted cytotoxic T-cell epitopes of the respiratory syncytial virus fusion protein. J Virol (2000) 0.97
C5 modulates airway hyperreactivity and pulmonary eosinophilia during enhanced respiratory syncytial virus disease by decreasing C3a receptor expression. J Virol (2006) 0.96
Respiratory syncytial virus: current progress in vaccine development. Viruses (2013) 0.95
Novel role of CD8(+) T cells and major histocompatibility complex class I genes in the generation of protective CD4(+) Th1 responses during retrovirus infection in mice. J Virol (2002) 0.93
Pulmonary eosinophilia is attenuated by early responding CD8(+) memory T cells in a murine model of RSV vaccine-enhanced disease. Viral Immunol (2009) 0.93
Regulatory T cells prevent Th2 immune responses and pulmonary eosinophilia during respiratory syncytial virus infection in mice. J Virol (2013) 0.92
Brief History and Characterization of Enhanced Respiratory Syncytial Virus Disease. Clin Vaccine Immunol (2015) 0.92
Severe acute respiratory syndrome (SARS) S protein production in plants: development of recombinant vaccine. Proc Natl Acad Sci U S A (2005) 0.91
Characterization of respiratory syncytial virus M- and M2-specific CD4 T cells in a murine model. J Virol (2009) 0.90
Epigenetic control of interferon-gamma expression in CD8 T cells. J Immunol Res (2015) 0.90
Cytotoxic T-lymphocyte precursor frequencies in BALB/c mice after acute respiratory syncytial virus (RSV) infection or immunization with a formalin-inactivated RSV vaccine. J Virol (1998) 0.88
Mapping and characterization of the primary and anamnestic H-2(d)-restricted cytotoxic T-lymphocyte response in mice against human metapneumovirus. J Virol (2007) 0.88
Identification of immunodominant epitopes derived from the respiratory syncytial virus fusion protein that are recognized by human CD4 T cells. J Virol (2003) 0.88
Baculovirus-based Vaccine Displaying Respiratory Syncytial Virus Glycoprotein Induces Protective Immunity against RSV Infection without Vaccine-Enhanced Disease. Immune Netw (2012) 0.87
Pulmonary eosinophilia requires interleukin-5, eotaxin-1, and CD4+ T cells in mice immunized with respiratory syncytial virus G glycoprotein. J Leukoc Biol (2008) 0.87
Neonatal antibody responses are attenuated by interferon-γ produced by NK and T cells during RSV infection. Proc Natl Acad Sci U S A (2013) 0.86
Recombinant influenza virus carrying the respiratory syncytial virus (RSV) F85-93 CTL epitope reduces RSV replication in mice. J Virol (2013) 0.85
Recombinant simian varicella viruses expressing respiratory syncytial virus antigens are immunogenic. J Gen Virol (2008) 0.85
Sub-nucleocapsid nanoparticles: a nasal vaccine against respiratory syncytial virus. PLoS One (2008) 0.84
Effects of cocaine administration to influenza virus-immunized mice on cytokine profiles of individual splenic CD4+ and CD8+ T cells. Clin Exp Immunol (1999) 0.84
Determining the breadth of the respiratory syncytial virus-specific T cell response. J Virol (2013) 0.83
Additive protection induced by mixed virus-like particles presenting respiratory syncytial virus fusion or attachment glycoproteins. Antiviral Res (2014) 0.82
Pre-existing virus-specific CD8(+) T-cells provide protection against pneumovirus-induced disease in mice. Vaccine (2012) 0.82
Central role of dendritic cells in shaping the adaptive immune response during respiratory syncytial virus infection. Future Virol (2011) 0.81
A novel respiratory syncytial virus (RSV) F subunit vaccine adjuvanted with GLA-SE elicits robust protective TH1-type humoral and cellular immunity in rodent models. PLoS One (2015) 0.80
Innate and adaptive immune response to pneumonia virus of mice in a resistant and a susceptible mouse strain. Viruses (2013) 0.80
CD8+ T cells and immunoregulatory networks in asthma. Springer Semin Immunopathol (2003) 0.79
Lethal host-versus-graft disease and hypereosinophilia in the absence of MHC I-T-cell interactions. J Clin Invest (2000) 0.79
Absence of vaccine-enhanced RSV disease and changes in pulmonary dendritic cells with adenovirus-based RSV vaccine. Virol J (2011) 0.79
RNA interference inhibits respiratory syncytial virus replication and disease pathogenesis without inhibiting priming of the memory immune response. J Virol (2008) 0.79
Specificity, restriction and effector mechanisms of immunoregulatory CD8 T cells. Immunology (2001) 0.79
CD8+ TCR transgenic strains expressing public versus private TCR targeting the respiratory syncytial virus K(d)M2(82-90) epitope demonstrate similar functional profiles. PLoS One (2014) 0.78
Development of safe and effective RSV vaccine by modified CD4 epitope in G protein core fragment (Gcf). PLoS One (2014) 0.78
Expansion of regulatory CD8+ CD25+ T cells after neonatal alloimmunization. Clin Exp Immunol (2010) 0.77
Fas ligand is required for the development of respiratory syncytial virus vaccine-enhanced disease. J Immunol (2009) 0.77
Universal vaccine against respiratory syncytial virus A and B subtypes. PLoS One (2017) 0.76
The increased type-1 and type-2 chemokine levels in children with acute RSV infection alter the development of adaptive immune responses. Biomed Res Int (2014) 0.75
Steric recognition of T-cell receptor contact residues is required to map mutant epitopes by immunoinformatical programmes. Immunology (2012) 0.75
Need for a safe vaccine against respiratory syncytial virus infection. Korean J Pediatr (2012) 0.75
In Hot Pursuit of the First Vaccine Against Respiratory Syncytial Virus. Yonsei Med J (2016) 0.75
Development of a reverse genetics system for respiratory syncytial virus long strain and an immunogenicity study of the recombinant virus. Virol J (2014) 0.75
Cationic liposome-mediated enhanced generation of human HLA-restricted RSV-specific CD8+ CTL+. J Clin Immunol (2002) 0.75
Recombinant baculovirus-based vaccine expressing M2 protein induces protective CD8(+) T-cell immunity against respiratory syncytial virus infection. J Microbiol (2017) 0.75
Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol (1986) 35.41
TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu Rev Immunol (1989) 31.72
Development of TH1 CD4+ T cells through IL-12 produced by Listeria-induced macrophages. Science (1993) 19.80
Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am J Epidemiol (1969) 10.85
Normal development of mice deficient in beta 2M, MHC class I proteins, and CD8+ T cells. Science (1990) 8.17
The presence of interleukin 4 during in vitro priming determines the lymphokine-producing potential of CD4+ T cells from T cell receptor transgenic mice. J Exp Med (1992) 7.80
In vivo effector function of influenza virus-specific cytotoxic T lymphocyte clones is highly specific. J Exp Med (1984) 6.27
Interleukin 12 acts directly on CD4+ T cells to enhance priming for interferon gamma production and diminishes interleukin 4 inhibition of such priming. Proc Natl Acad Sci U S A (1993) 6.12
Differential regulation of T helper phenotype development by interleukins 4 and 10 in an alpha beta T-cell-receptor transgenic system. Proc Natl Acad Sci U S A (1992) 5.55
Field evaluation of a respiratory syncytial virus vaccine and a trivalent parainfluenza virus vaccine in a pediatric population. Am J Epidemiol (1969) 4.93
Roles of alpha beta and gamma delta T cell subsets in viral immunity. Annu Rev Immunol (1992) 4.83
The effect of antigen dose on CD4+ T helper cell phenotype development in a T cell receptor-alpha beta-transgenic model. J Exp Med (1995) 4.21
Purified protein derivative of Mycobacterium tuberculosis and excretory-secretory antigen(s) of Toxocara canis expand in vitro human T cells with stable and opposite (type 1 T helper or type 2 T helper) profile of cytokine production. J Clin Invest (1991) 4.08
Nucleotide sequence of the G protein gene of human respiratory syncytial virus reveals an unusual type of viral membrane protein. Proc Natl Acad Sci U S A (1985) 3.93
Antiproliferative effect of IFN-gamma in immune regulation. III. Differential selection of TH1 and TH2 murine helper T lymphocyte clones using recombinant IL-2 and recombinant IFN-gamma. J Immunol (1989) 3.78
Establishment of stable, cell-mediated immunity that makes "susceptible" mice resistant to Leishmania major. Science (1992) 3.59
Cytotoxic T cells clear virus but augment lung pathology in mice infected with respiratory syncytial virus. J Exp Med (1988) 3.39
Role of NK1.1+ T cells in a TH2 response and in immunoglobulin E production. Science (1995) 3.37
Distinct types of lung disease caused by functional subsets of antiviral T cells. J Exp Med (1994) 2.99
Priming immunization determines T helper cytokine mRNA expression patterns in lungs of mice challenged with respiratory syncytial virus. J Immunol (1993) 2.92
Asthma and immunoglobulin E antibodies after respiratory syncytial virus bronchiolitis: a prospective cohort study with matched controls. Pediatrics (1995) 2.87
Role of cytokines in the differentiation of CD4+ T-cell subsets in vivo. Immunol Rev (1991) 2.85
Generation, translocation, and presentation of MHC class I-restricted peptides. Annu Rev Biochem (1995) 2.76
Regulation of IgE responses to inhaled antigen in mice by antigen-specific gamma delta T cells. Science (1994) 2.66
Antigen presentation pathways to class I and class II MHC-restricted T lymphocytes. Immunol Rev (1987) 2.64
Pulmonary eosinophilic response to respiratory syncytial virus infection in mice sensitized to the major surface glycoprotein G. Int Immunol (1992) 2.25
Expression of the fusion protein of human respiratory syncytial virus from recombinant vaccinia virus vectors and protection of vaccinated mice. J Virol (1987) 1.98
Cytotoxic T-cell response to respiratory syncytial virus in mice. J Virol (1985) 1.92
Expression of the major glycoprotein G of human respiratory syncytial virus from recombinant vaccinia virus vectors. Proc Natl Acad Sci U S A (1986) 1.85
Pathogen-induced Th1 phenotype development in CD4+ alpha beta-TCR transgenic T cells is macrophage dependent. Int Immunol (1993) 1.80
Immunological determinants of disease caused by respiratory syncytial virus. Trends Microbiol (1996) 1.76
Generation of atypical pulmonary inflammatory responses in BALB/c mice after immunization with the native attachment (G) glycoprotein of respiratory syncytial virus. J Virol (1996) 1.69
Beta 2-microglobulin-dependent NK1.1+ T cells are not essential for T helper cell 2 immune responses. J Exp Med (1996) 1.68
Anti-IL-4 treatment at immunization modulates cytokine expression, reduces illness, and increases cytotoxic T lymphocyte activity in mice challenged with respiratory syncytial virus. J Clin Invest (1994) 1.67
Characterization of murine lung dendritic cells: similarities to Langerhans cells and thymic dendritic cells. J Exp Med (1990) 1.65
CD4+ T cells clear virus but augment disease in mice infected with respiratory syncytial virus. Comparison with the effects of CD8+ T cells. Clin Exp Immunol (1992) 1.57
The 22,000-kilodalton protein of respiratory syncytial virus is a major target for Kd-restricted cytotoxic T lymphocytes from mice primed by infection. J Virol (1990) 1.57
Structure of peptides associated with MHC class I molecules. Curr Opin Immunol (1994) 1.53
Antigen presentation: structural themes and functional variations. Immunol Today (1991) 1.53
Human cytotoxic T cells stimulated by antigen on dendritic cells recognize the N, SH, F, M, 22K, and 1b proteins of respiratory syncytial virus. J Virol (1992) 1.51
Cytolytic T-lymphocyte responses to respiratory syncytial virus: effector cell phenotype and target proteins. J Virol (1990) 1.50
Virus-specific memory and effector T lymphocytes exhibit different cytokine responses to antigens during experimental murine respiratory syncytial virus infection. J Virol (1997) 1.48
Immunization of mice with vaccinia virus-M2 recombinant induces epitope-specific and cross-reactive Kd-restricted CD8+ cytotoxic T cells. J Virol (1993) 1.47
Phenotypic and functional characterization of T cell lines specific for individual respiratory syncytial virus proteins. J Immunol (1993) 1.45
Interleukin 4 production by CD4+ T cells from allergic individuals is modulated by antigen concentration and antigen-presenting cell type. J Exp Med (1995) 1.44
IL-12 inhibits the production of IL-4 and IL-10 in allergen-specific human CD4+ T lymphocytes. J Immunol (1995) 1.40
Beta 2-microglobulin-dependent T cells are dispensable for allergen-induced T helper 2 responses. J Exp Med (1996) 1.37
The relationship of RSV-specific immunoglobulin E antibody responses in infancy, recurrent wheezing, and pulmonary function at age 7-8 years. Pediatr Pulmonol (1993) 1.29
Interleukin-11: stimulation in vivo and in vitro by respiratory viruses and induction of airways hyperresponsiveness. J Clin Invest (1996) 1.27
Enhanced pulmonary pathology associated with the use of formalin-inactivated respiratory syncytial virus vaccine in cotton rats is not a unique viral phenomenon. Vaccine (1993) 1.11
CD4 T cell development and cytokine polarization: an overview. J Leukoc Biol (1995) 0.96
The cytokines IL-4, IFN-gamma, and IL-12 regulate the development of subsets of memory effector helper T cells in vitro. J Immunol (1995) 0.95
Elimination of IgE regulatory rat CD8+ T cells in vivo differentially modulates interleukin-4 and interferon-gamma but not interleukin-2 production by splenic T cells. Immunology (1993) 0.94
Viral antigen presentation and MHC assembly. Semin Immunol (1992) 0.87
Development of a novel subunit vaccine that protects cotton rats against both human respiratory syncytial virus and human parainfluenza virus type 3. J Gen Virol (1993) 0.87
Vaccination with a heterologous respiratory syncytial virus chimeric FG glycoprotein demonstrates significant subgroup cross-reactivity. Vaccine (1993) 0.84
Acquisition of lymphokine-producing phenotype by CD4+ T cells. J Allergy Clin Immunol (1994) 0.82
The effect of parainfluenza 3 infection on guinea pig basophil and lung mast cell histamine release. Am Rev Respir Dis (1989) 0.80
The contrasting effects of CD8+ T cells on primary, established and Nippostrongylus brasiliensis-induced IgE responses. Immunology (1996) 0.78
In vivo effector function of influenza virus-specific cytotoxic T lymphocyte clones is highly specific. J Exp Med (1984) 6.27
Differences in antigen presentation to MHC class I-and class II-restricted influenza virus-specific cytolytic T lymphocyte clones. J Exp Med (1986) 5.11
Immunologic recognition of influenza virus-infected cells. I. Generation of a virus-strain specific and a cross-reactive subpopulation of cytotoxic T cells in the response to type A influenza viruses of different subtypes. Cell Immunol (1977) 3.60
Response to influenza infection in mice with a targeted disruption in the interferon gamma gene. J Exp Med (1993) 2.88
Infectious Sindbis virus transient expression vectors for studying antigen processing and presentation. Proc Natl Acad Sci U S A (1992) 2.86
Heterogeneity and specificity of cloned lines of influenza-virus specific cytotoxic T lymphocytes. J Exp Med (1981) 2.71
Immunologic recognition of influenza virus-infected cells. II. Expression of influenza A matrix protein on the infected cell surface and its role in recognition by cross-reactive cytotoxic T cells. J Exp Med (1977) 2.68
Resistance to and recovery from lethal influenza virus infection in B lymphocyte-deficient mice. J Exp Med (1997) 2.67
Influenza virus-specific CD4+ T helper type 2 T lymphocytes do not promote recovery from experimental virus infection. J Exp Med (1994) 2.53
Interaction between complement receptor gC1qR and hepatitis C virus core protein inhibits T-lymphocyte proliferation. J Clin Invest (2000) 2.25
Cytotoxic T lymphocyte recognition of the influenza hemagglutinin gene product expressed by DNA-mediated gene transfer. J Exp Med (1984) 2.10
Expression of a murine polyclonal T cell receptor marker correlates with the use of specific members of the V beta 8 gene segment subfamily. J Exp Med (1987) 1.96
Role of viral infectivity in the induction of influenza virus-specific cytotoxic T cells. J Exp Med (1978) 1.91
The analysis of the monoclonal immune response to influenza virus. I. Production of monoclonal anti-viral antibodies in vitro. Eur J Immunol (1975) 1.81
Immunopathology in RSV infection is mediated by a discrete oligoclonal subset of antigen-specific CD4(+) T cells. Immunity (2001) 1.69
Recognition of pre-processed endogenous antigen by class I but not class II MHC-restricted T cells. Nature (1989) 1.67
Specificity of cytotoxicity T cells directed to influenza virus hemagglutinin. J Exp Med (1979) 1.64
On the role of the transmembrane anchor sequence of influenza hemagglutinin in target cell recognition by class I MHC-restricted, hemagglutinin-specific cytolytic T lymphocytes. J Exp Med (1987) 1.58
Role of T-cell function in recovery from murine influenza infection. Cell Immunol (1979) 1.57
Structural and functional consequences of alveolar cell recognition by CD8(+) T lymphocytes in experimental lung disease. J Clin Invest (1998) 1.54
Influenza virus-specific human cytotoxic T cell clones: heterogeneity in antigenic specificity and restriction by class II MHC products. Cell Immunol (1984) 1.50
The attachment (G) glycoprotein of respiratory syncytial virus contains a single immunodominant epitope that elicits both Th1 and Th2 CD4+ T cell responses. J Immunol (2000) 1.50
Virus-specific memory and effector T lymphocytes exhibit different cytokine responses to antigens during experimental murine respiratory syncytial virus infection. J Virol (1997) 1.48
Expression of specific cytolytic activity by H-2I region-restricted, influenza virus-specific T lymphocyte clones. J Exp Med (1985) 1.46
Antigen form influences induction and frequency of influenza-specific class I and class II MHC-restricted cytolytic T lymphocytes. J Immunol (1988) 1.35
Simultaneous expression of H-2-restricted and alloreactive recognition by a cloned line of influenza virus-specific cytotoxic T lymphocytes. J Exp Med (1981) 1.34
Visualization and characterization of respiratory syncytial virus F-specific CD8(+) T cells during experimental virus infection. J Immunol (2001) 1.33
Fine specificity and antigen receptor expression among influenza virus-specific cytolytic T lymphocyte clones. J Immunol (1986) 1.29
Why can't cytotoxic T cells handle HIV? Proc Natl Acad Sci U S A (1995) 1.27
Induction of Th-1 and Th-2 responses by respiratory syncytial virus attachment glycoprotein is epitope and major histocompatibility complex independent. J Virol (1999) 1.25
CD8+ T cell recognition of an endogenously processed epitope is regulated primarily by residues within the epitope. J Exp Med (1992) 1.17
Partial activation of CD8+ T cells by a self-derived peptide. Nature (1995) 1.17
Class I major histocompatibility complex-restricted T lymphocyte recognition of the influenza hemagglutinin. Overlap between class I cytotoxic T lymphocytes and antibody sites. J Exp Med (1989) 1.11
Incomplete CD8(+) T lymphocyte differentiation as a mechanism for subdominant cytotoxic T lymphocyte responses to a viral antigen. J Exp Med (2000) 1.09
Cutting edge: lipid raft integrity affects the efficiency of MHC class I tetramer binding and cell surface TCR arrangement on CD8+ T cells. J Immunol (2001) 1.07
Regulation of interleukin 2 receptor expression on murine cytotoxic T lymphocyte clones. J Immunol (1984) 1.06
Perforin-independent CD8(+) T-cell-mediated cytotoxicity of alveolar epithelial cells is preferentially mediated by tumor necrosis factor-alpha: relative insensitivity to Fas ligand. Am J Respir Cell Mol Biol (1999) 1.05
Antigen-dependent regulation of interleukin 2 receptor expression on cloned human cytotoxic T lymphocytes. J Immunol (1984) 1.04
Features of target cell lysis by class I and class II MHC-restricted cytolytic T lymphocytes. J Immunol (1986) 1.03
Antigen-dependent proliferation of cloned continuous lines of H-2-restricted influenza virus-specific cytotoxic T lymphocytes. J Immunol (1981) 1.03
CD8(+) T cell-mediated injury in vivo progresses in the absence of effector T cells. J Exp Med (2001) 1.02
Characterization and in vivo distribution of influenza-virus-specific T-lymphocytes in the murine respiratory tract. Am Rev Respir Dis (1987) 1.01
Regulation of T lymphocyte proliferation. Interleukin 2-mediated induction of c-myb gene expression is dependent on T lymphocyte activation state. J Exp Med (1989) 1.01
A lung-specific neo-antigen elicits specific CD8+ T cell tolerance with preserved CD4+ T cell reactivity. Implications for immune-mediated lung disease. J Clin Invest (1996) 1.00
Activation of virus specific CTL clones: antigen-dependent regulation of interleukin 2 receptor expression. J Immunol (1985) 0.99
The weak CD8+ CTL response to an influenza hemagglutinin epitope reflects limited T cell availability. J Immunol (1996) 0.98
Nonconventional (TL-encoded) major histocompatibility complex molecules present processed viral antigen to cytotoxic T lymphocytes. J Exp Med (1991) 0.98
Type 2 cytokines predominate in the human CD4(+) T-lymphocyte response to Epstein-Barr virus nuclear antigen 1. J Virol (2000) 0.98
Class I MHC-restricted recognition of cells expressing a gene encoding a 41 amino acid product of the influenza hemagglutinin. J Immunol (1988) 0.97
Cytotoxic T lymphocytes recognize a cross-reactive epitope on the transmembrane region of influenza H1 and H2 hemagglutinins. Viral Immunol (1989) 0.96
Mycoplasma infection of cell cultures: thymidine incorporation of culture supernatants as a screening test. J Immunol (1984) 0.95
MIs locus recognition by a cloned line of H-2-restricted influenza virus-specific cytotoxic T lymphocytes. J Immunol (1981) 0.94
Recognition of the influenza hemagglutinin by class II MHC-restricted T lymphocytes and antibodies. I. Site definition and implications for antigen presentation and T lymphocyte recognition. J Immunol (1991) 0.94
Analysis of the humoral immune response to influenza virus in vitro. J Immunol (1976) 0.92
Stimulation of anti-influenza cytolytic T lymphocytes by CNBr cleavage fragments of the viral hemagglutinin. J Immunol (1981) 0.91
The recognition of a viral antigenic moiety by class I MHC-restricted cytolytic T lymphocytes is limited by the availability of the endogenously processed antigen. J Immunol (1990) 0.91
Presentation of newly synthesized glycoproteins to CD4+ T lymphocytes. An analysis using influenza hemagglutinin transport mutants. J Exp Med (1993) 0.90
Functional and structural considerations in the recognition of virus-infected cells by cytotoxic T lymphocytes. Contemp Top Mol Immunol (1978) 0.87
Sendai virus-specific, H-2-restricted cytotoxic T lymphocyte responses of nude mice grafted with allogeneic or semi-allogeneic thymus glands. J Exp Med (1980) 0.87
The requirement for proteasome activity class I major histocompatibility complex antigen presentation is dictated by the length of preprocessed antigen. J Exp Med (1996) 0.86
Characteristics of ATP-dependent peptide transport in isolated microsomes. J Immunol (1995) 0.86
Distinguishable pathways of viral antigen presentation to T lymphocytes. Immunol Res (1986) 0.85
Xyloside inhibits synthesis of the class II-associated chondroitin sulfate proteoglycan and antigen presentation events. J Immunol (1987) 0.85
Regulation of antigen processing and presentation to class I MHC restricted CD8+ T lymphocytes. Immunol Rev (1996) 0.83
Inducible expression of insulin receptors on T lymphocyte clones. J Exp Med (1982) 0.83
Recognition of an immunoglobulin VH epitope by influenza virus-specific class I major histocompatibility complex-restricted cytolytic T lymphocytes. J Exp Med (1994) 0.82
Expression of H-2I region-restricted cytolytic activity by an Lyt-2+ influenza virus-specific T lymphocyte clone. J Immunol (1985) 0.79
Anti-T cell receptor antibodies fail to inhibit specific lysis by CTL clones but activate lytic activity for irrelevant targets. J Immunol (1987) 0.79
Macrophage procoagulant-inducing activity of influenza-specific effector T cells. Cell Immunol (1984) 0.79
Differences in expression of MHC products between several H-2-restricted CTL clones. J Immunol (1982) 0.78
Partial activation of foreign antigen specific T lymphocytes by a self peptide: possible roles of altered peptide ligands in regulating T lymphocyte mediated immune response. J Mol Med (Berl) (1996) 0.77
A method for the preparation of Vicia villosa lectin and a rosette procedure for fractionation of lectin-binding lymphocytes. J Immunol Methods (1981) 0.77
Target-cell recognition by cloned lines of influenza virus-specific cytotoxic T lymphocytes. Selective inhibition by a monoclonal H-2-specific antibody. Immunogenetics (1982) 0.75
A helper factor needed for the generation of mouse cytolytic T lymphocytes is made by tumor cell lines, cloned T cells, and spleen cells exposed to a variety of stimuli. J Immunol (1984) 0.75
Endogenous presentation of a nascent antigenic epitope to CD8+ CTL is more efficient than exogenous presentation. Immunol Cell Biol (1996) 0.75
Stable expression of cytolytic activity by influenza virus-specific cytotoxic T lymphocytes. J Immunol (1985) 0.75
Recognition of a sequestered self peptide by influenza virus-specific CD8+ cytolytic T lymphocytes. J Immunol (2000) 0.75